MannKind (NASDAQ:MNKD – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
Institutional & Insider Ownership
49.5% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 1.7% of MDxHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares MannKind and MDxHealth”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MannKind | $348.97 million | 3.46 | $5.86 million | ($0.13) | -28.85 |
| MDxHealth | $114.02 million | 0.31 | -$33.52 million | ($0.72) | -0.98 |
MannKind has higher revenue and earnings than MDxHealth. MannKind is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
MannKind has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for MannKind and MDxHealth, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MannKind | 2 | 1 | 7 | 0 | 2.50 |
| MDxHealth | 1 | 1 | 3 | 0 | 2.40 |
MannKind currently has a consensus price target of $8.34, indicating a potential upside of 122.50%. MDxHealth has a consensus price target of $2.17, indicating a potential upside of 207.50%. Given MDxHealth’s higher probable upside, analysts plainly believe MDxHealth is more favorable than MannKind.
Profitability
This table compares MannKind and MDxHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MannKind | -11.08% | -11.21% | -6.31% |
| MDxHealth | -33.46% | N/A | -24.25% |
Summary
MannKind beats MDxHealth on 10 of the 14 factors compared between the two stocks.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
